IL135324A0 - Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders - Google Patents

Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Info

Publication number
IL135324A0
IL135324A0 IL13532498A IL13532498A IL135324A0 IL 135324 A0 IL135324 A0 IL 135324A0 IL 13532498 A IL13532498 A IL 13532498A IL 13532498 A IL13532498 A IL 13532498A IL 135324 A0 IL135324 A0 IL 135324A0
Authority
IL
Israel
Prior art keywords
apoa
agonists
native
gene therapy
apolipoprotein
Prior art date
Application number
IL13532498A
Other languages
English (en)
Original Assignee
Dasseux Jean Louis
Sekul Renate
Buttner Klaus
Cornut Isabelle
Metz Gunther
Dufourcq Jean
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dasseux Jean Louis, Sekul Renate, Buttner Klaus, Cornut Isabelle, Metz Gunther, Dufourcq Jean filed Critical Dasseux Jean Louis
Publication of IL135324A0 publication Critical patent/IL135324A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Optics & Photonics (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IL13532498A 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders IL135324A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/940,136 US6518412B1 (en) 1997-09-29 1997-09-29 Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
PCT/US1998/020329 WO1999016409A2 (en) 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Publications (1)

Publication Number Publication Date
IL135324A0 true IL135324A0 (en) 2001-05-20

Family

ID=25474297

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13532498A IL135324A0 (en) 1997-09-29 1998-09-28 Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders

Country Status (17)

Country Link
US (4) US6518412B1 (de)
EP (1) EP1039934B1 (de)
JP (1) JP2003525565A (de)
KR (1) KR100650975B1 (de)
CN (1) CN100345588C (de)
AT (1) ATE323510T1 (de)
AU (1) AU758307B2 (de)
CA (1) CA2304814A1 (de)
DE (1) DE69834267T2 (de)
ES (1) ES2263221T3 (de)
HU (1) HU225821B1 (de)
IL (1) IL135324A0 (de)
NO (1) NO20001601L (de)
NZ (1) NZ503720A (de)
PL (1) PL193662B1 (de)
RU (1) RU2222545C2 (de)
WO (1) WO1999016409A2 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
JP4794707B2 (ja) * 1998-11-17 2011-10-19 ソニー株式会社 端末装置、課金システム、データ処理方法
CA2402772A1 (en) * 2000-03-13 2001-09-20 Amgen Inc. Apolipoprotein-a-i regulation of t-cell signalling
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7199102B2 (en) * 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) * 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7144862B2 (en) * 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7723303B2 (en) * 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7470659B2 (en) * 2001-12-07 2008-12-30 The Regents Of The University Of California Methods to increase reverse cholesterol transport in the retinal pigment epithelium (RPE) and Bruch's membrane (BM)
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
US7959659B2 (en) * 2004-01-02 2011-06-14 Advanced Cardiovascular Systems, Inc. High-density lipoprotein coated medical devices
US20060205669A1 (en) * 2004-09-16 2006-09-14 The Regents Of The University Of California G-type peptides and other agents to ameliorate atherosclerosis and other pathologies
ATE469174T1 (de) 2004-10-15 2010-06-15 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
WO2006063132A2 (en) 2004-12-06 2006-06-15 The Regents Of The University Of California Methods for improving the structure and function of arterioles
US20080293639A1 (en) * 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
CA2653840A1 (en) * 2006-06-01 2007-12-06 Institut De Cardiologie De Montreal Use of a peptide/phospholipid complex acting as a reverse lipid transport agonist for treatment of valvular stenosis
EP2041174A2 (de) * 2006-06-16 2009-04-01 Lipid Sciences, Inc. Neue, den lipidausstrom fördernde peptide
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
US20080227686A1 (en) * 2006-06-16 2008-09-18 Lipid Sciences, Inc. Novel Peptides that Promote Lipid Efflux
AU2007285775B2 (en) * 2006-08-17 2011-03-03 Sanofi Pasteur Ltd. Immunogenic PcpA polypeptides and uses thereof
WO2008039843A2 (en) * 2006-09-26 2008-04-03 Lipid Sciences, Inc. Novel peptides that promote lipid efflux
AU2008296478B9 (en) * 2007-08-28 2015-03-19 The Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8557767B2 (en) 2007-08-28 2013-10-15 Uab Research Foundation Synthetic apolipoprotein E mimicking polypeptides and methods of use
US8101565B2 (en) * 2007-09-20 2012-01-24 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US8044021B2 (en) * 2007-09-20 2011-10-25 Abbott Cardiovascular Systems Inc. Sustained release of apo A-I mimetic peptides and methods of treatment
US7985727B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Apo A-I mimetic peptides and methods of treatment
US9173890B2 (en) 2007-09-20 2015-11-03 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
US7985728B1 (en) 2007-09-20 2011-07-26 Abbott Cardiovascular Systems Inc. Sustained release of Apo A-I mimetic peptides and methods of treatment
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase
LT2939683T (lt) * 2009-02-16 2017-03-27 Cerenis Therapeutics Holding Sa Apolipoproteino a-i mimetikai
US8176412B2 (en) * 2009-08-25 2012-05-08 International Business Machines Corporation Generating formatted documents
MX2013002145A (es) 2010-08-30 2013-04-03 Hoffmann La Roche Tetranectina-apolipoproteina a-i, particulas lipidicas que la contienen y utilizacion de la misma.
EP2673296B1 (de) 2011-02-07 2018-10-24 Cerenis Therapeutics Holding SA Lipoproteinkomplexe, ihre herstellung und verwendung
WO2012162392A1 (en) 2011-05-23 2012-11-29 Timothy Hla Endothelium protective materials and methods of use
BR112013033562A2 (pt) 2011-08-25 2017-02-14 Hoffmann La Roche proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas
CN104250288B (zh) * 2013-06-28 2018-02-27 清华大学 两亲性α螺旋自组装肽及其应用
WO2015173633A2 (en) 2014-05-02 2015-11-19 Cerenis Therapeutics Holding Sa Hdl therapy markers
MX383117B (es) 2014-07-31 2025-03-13 Anji Pharmaceuticals Inc Péptidos miméticos de la apoe y mayor potencia para depurar el colesterol en plasma.
US12257352B2 (en) * 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
CN115300609A (zh) * 2021-05-08 2022-11-08 西湖大学 缺氧诱导脂滴相关蛋白(hilpda)在预防或治疗高血脂相关疾病中的应用
WO2025128566A1 (en) * 2023-12-13 2025-06-19 University Of Kentucky Research Foundation Synthetic high-density lipoprotein and method for treating sepsis and related conditions

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH621479A5 (de) 1977-08-05 1981-02-13 Battelle Memorial Institute
CA1173360A (en) 1979-06-22 1984-08-28 Jurg Schrank Pharmaceutical preparations
DE3241102A1 (de) 1982-11-06 1984-05-10 A. Nattermann & Cie GmbH, 5000 Köln Imidazolylalkylthienyl-tetrahydropyridazine und verfahren zu ihrer herstellung
US4643988A (en) 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
US4880635B1 (en) 1984-08-08 1996-07-02 Liposome Company Dehydrated liposomes
US4857319A (en) 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
ATE171192T1 (de) 1992-06-12 1998-10-15 Innogenetics Nv Peptide und proteine, verfahren zur ihren herstellung und die verwendung als cholesterol- annehmer
US5674855A (en) 1992-08-12 1997-10-07 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
SE9203753D0 (sv) 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5643757A (en) * 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
EP0755268A1 (de) * 1994-04-11 1997-01-29 Baylor College Of Medicine Zusammensetzungen und verfahren zur behandlung von erkrankungen durch gentherapie
RU2043116C1 (ru) * 1994-05-04 1995-09-10 Александр Иванович Арчаков Пептид апов-рецептора, ответственный за связывание липопротеинов низкой плотности
FR2723741A1 (fr) * 1994-08-16 1996-02-23 Fournier Sca Lab Peptides inhibiteurs de la proteine de transfert des esters de cholesterol et leur utilisation en therapeutique
FR2734568B1 (fr) 1995-05-22 1997-06-20 Rhone Poulenc Rorer Sa Nouveaux variants de l'apolipoproteine
DK0853480T3 (da) * 1995-09-09 2003-05-05 Hoffmann La Roche Anvendelse af en thienotriazolodiazepin til forøgelse af apolipoprotein A-I-niveauer
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders

Also Published As

Publication number Publication date
CA2304814A1 (en) 1999-04-08
US6844327B2 (en) 2005-01-18
DE69834267T2 (de) 2007-01-04
EP1039934B1 (de) 2006-04-19
US20080050351A1 (en) 2008-02-28
CN1303298A (zh) 2001-07-11
US20050148513A1 (en) 2005-07-07
KR100650975B1 (ko) 2006-11-29
JP2003525565A (ja) 2003-09-02
HU225821B1 (en) 2007-10-29
US7250407B2 (en) 2007-07-31
NZ503720A (en) 2002-10-25
HUP0003924A3 (en) 2005-12-28
DE69834267D1 (de) 2006-05-24
HUP0003924A2 (hu) 2001-01-29
KR20010030806A (ko) 2001-04-16
NO20001601D0 (no) 2000-03-28
WO1999016409A2 (en) 1999-04-08
EP1039934A1 (de) 2000-10-04
AU758307B2 (en) 2003-03-20
PL193662B1 (pl) 2007-03-30
NO20001601L (no) 2000-05-26
PL358529A1 (en) 2004-08-09
ATE323510T1 (de) 2006-05-15
AU9671498A (en) 1999-04-23
US20030208059A1 (en) 2003-11-06
CN100345588C (zh) 2007-10-31
RU2222545C2 (ru) 2004-01-27
EP1039934A4 (de) 2002-11-27
US6518412B1 (en) 2003-02-11
ES2263221T3 (es) 2006-12-01

Similar Documents

Publication Publication Date Title
IL135324A0 (en) Gene therapy approaches to supply apolipoprotein a-i agonists and their use to treat dyslipidemic disorders
ES2525677T3 (es) Celulasas, genes que las codifican y usos de las mismas
EP1003379A4 (de) Neuartige phytase
GB0202556D0 (en) Novel Protein
DE69942365D1 (de) Gezielte zufuhr von pharmazeutischen agenzien zu verletzten geweben
ZA99133B (en) Transgenic rabbit that expresses a functional human lipoprotein (A).
IL135688A0 (en) Human checkpoint kinase, hcds1, compositions and methods
DE69635349D1 (de) Nukleotidsequenzen, proteine, medikamente und diagnoseagentien zur anwendung in krebsbehandlung
PT815233E (pt) NOVAS CITOCINAS AVIÁRIAS E SEQUjNCIAS GENÉTICAS QUE AS CODIFICAM
PL313445A1 (en) Grb3-3 gene, variants thereof and their use
WO1998011234A3 (en) Human protein kinases
FR2773079B1 (fr) Cible de traitement de l'atherosclerose, de l'obesite et du diabete de type ii
IL174645A0 (en) MODIFIED cDNA FOR HIGH EXPRESSION LEVELS OF FACTOR VIII AND ITS DERIVATIVES
ATE325812T1 (de) Menschliches, gebärmutterkrebs-spezifisches suppressorprotein, für das protein kodieres polynukleotid, mit dem polynukleotid transformierte zelle und verfahren zur unterdrückung der proliferation von krebszellen unter verwendung des expressionsvektors
ATE387494T1 (de) Hitzelabile desoxyribonuklease i-varianten